Oncology Institute (NASDAQ:STLN – Get Free Report) had its price target decreased by equities research analysts at Lake Street Capital from $10.00 to $8.00 in a report released on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. Lake Street Capital‘s price objective points to a potential upside of 120.99% from the stock’s current price.
STLN has been the topic of several other research reports. BTIG Research increased their price target on shares of Oncology Institute from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday. Needham & Company LLC boosted their price objective on shares of Oncology Institute from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, October 14th. B. Riley Financial restated a “buy” rating and set a $10.00 price objective (down from $11.00) on shares of Oncology Institute in a research report on Friday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oncology Institute in a research note on Tuesday, November 3rd. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $9.25.
Read Our Latest Analysis on Oncology Institute
Oncology Institute Price Performance
STLN stock opened at $3.62 on Friday. The company has a market cap of $357.80 million, a PE ratio of -12.48 and a beta of 0.44. The stock’s fifty day moving average price is $6.43. Oncology Institute has a fifty-two week low of $2.32 and a fifty-two week high of $7.13.
Oncology Institute (NASDAQ:STLN – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The firm had revenue of $169.77 million for the quarter. Equities research analysts expect that Oncology Institute will post -0.21 earnings per share for the current fiscal year.
Insider Transactions at Oncology Institute
In other Oncology Institute news, Director Brad Hively sold 298,853 shares of Oncology Institute stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $6.51, for a total value of $1,945,533.03. Following the transaction, the director owned 411,976 shares in the company, valued at $2,681,963.76. The trade was a 42.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett bought 12,000 shares of the stock in a transaction on Friday, August 14th. The shares were acquired at an average cost of $6.54 per share, with a total value of $78,480.00. Following the purchase, the insider owned 10,660,858 shares of the company’s stock, valued at approximately $69,722,011.32. This represents a 0.11% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders own 4.40% of the company’s stock.
Institutional Investors Weigh In On Oncology Institute
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in Oncology Institute during the 2nd quarter worth approximately $25,787,000. State Street Corp acquired a new stake in Oncology Institute in the second quarter valued at approximately $8,432,000. Manatuck Hill Partners LLC acquired a new stake in Oncology Institute in the second quarter valued at approximately $2,444,000. Walleye Capital LLC acquired a new stake in Oncology Institute in the second quarter valued at approximately $2,421,000. Finally, Bank of America Corp DE bought a new stake in shares of Oncology Institute during the second quarter worth $2,129,000. 36.86% of the stock is owned by institutional investors.
About Oncology Institute
The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals.
The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs.
Read More
- Five stocks we like better than Oncology Institute
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for Oncology Institute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Institute and related companies with MarketBeat.com's FREE daily email newsletter.
